Table 3

Median (IQR) values of IL-6, IL-8, CTX-II, RANKL and OPG serum levels at baseline and 8 weeks after initiation of TCZ treatment

BaselineWeek 8P value
IL-6 (pg/mL)
 Total9.1 (1.1–14.8)34.2 (25.4–51.9)0.001
 Responders3.6 (1.2–10.7)33.7 (20.2–47.8)0.005
 Non-responders16.9 (13.4–20.8)34.2 (32.0–48.3)0.068
IL-8 (pg/mL)
 Total15.3 (11.5–20.1)15.3 (12.8–21.5)0.638
 Responders14.6 (10.2–20.1)15.8 (11.2–21.5)0.445
 Non-responders19.1 (14.2–23.2)15.3 (13.6–35.5)1.000
RANKL (pmol/mL)
 Total0.11 (0.05–0.25)0.20 (0.15–0.38)0.013
 Responders0.09 (0.05–0.27)0.21 (0.18–0.38)0.008
 Non-responders0.18 (0.05–0.28)0.15 (0.08–0.69)0.465
OPG (pmol/L)
 Total7.04 (5.04–9.79)7.20 (5.28–8.65)0.272
 Responders7.33 (5.04–10.25)7.20 (5.28–8.65)0.285
 Non-responders6.62 (4.79–9.14)6.39 (4.57–8.89)1.000
CTX-II (ng/mL)
 Total1525.1(1178.4–1672.6)1715.1 (1393.1–2660.1)0.433
 Responders1518.0(1172.3–1647.9)1782.54(1310.6–2668.3)0.169
 Non-responders1598.8(1369.9–3242.6)1579.18(1420.0–2600.2)0.465
  • CTXII, C-terminal crosslinked telopeptide type II collagen; IL-6, interleukin-6; IL-8, interleukin-8; OPG, osteoprotegerin; RANKL, receptor activator for nuclear factor-κB ligand.